Mammary Carcinoma, Squamous Cell Carcinoma, AGASACA, and Melanoma Clinical Trial

Refer your canine mammary or squamous cell carcinoma, AGASACA, and melanoma patients

Benefits and Participation 

  • Owners are financially responsible for the initial exam and screening tests to determine eligibility. 
  • Following the initial exam and screening, the remainder of this trial is funded for up to 2 months of treatment including tumor biopsy, recheck exams, bloodwork, and chemotherapy. 
  • Recheck visits for blood draws and monitoring are required and covered by the study. 

Inclusion Criteria

  • Diagnosis of mammary carcinoma, melanoma, squamous cell carcinoma, or apocrine anal sac adenocarcinoma (AGASACA) 
  • Measurable tumor on physical exam 
  • Prior cancer treatment is allowed, but dogs must have cancer progression at the time of enrollment 
  • Pet must be otherwise healthy

Clinical Trial Background

  • Cancer is ranked as the top cause of death in dogs. 
  • New anti-cancer therapies are desperately needed. 
  • Palbociclib is an oral chemotherapy drug used in various human cancers. 
  • Palbociclib has the potential to treat many canine cancers, however, the ideal dose has yet to be established in dogs. 


Please direct any questions regarding the enrollment of a patient to the Auburn Oncology Service.

Phone: (334) 844-4690 

Mammary Carcinoma, Squamous Cell Carcinoma, AGASACA, and Melanoma Clinical Trial Flyer (PDF)